Zobrazeno 1 - 10
of 19
pro vyhledávání: '"XueYan Liao"'
Autor:
Shaomin Chen, Zhifang Ying, Yan Liu, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, Yong Zhang, Guixiu Liu, Weiwei Zhao, Rong Fu, Qiong Shou, Minghuan Zheng, Xueyan Liao, Yingmei Tu, Jon Stek, Jonathan Hartzel, Changgui Li, Jikai Zhang
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThis open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three dos
Externí odkaz:
https://doaj.org/article/0433b9f021254813a1d04914c2993518
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 6, Pp 1272-1278 (2017)
A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunog
Externí odkaz:
https://doaj.org/article/90f83466c72b46d493d8087e83ca874c
Autor:
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Yingping Chen, Xiaosong Hu, Rong Fu, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Zhiping Chen
Publikováno v:
Vaccine. 40:3263-3271
The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3, open-label study (NCT03903562) compared 9vHPV vaccine immunogenicity and safety in Chinese f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b90590c05f36b88df824c542cf178d
https://doi.org/10.1016/j.vaccine.2022.02.061
https://doi.org/10.1016/j.vaccine.2022.02.061
Autor:
Zhuhang Huang, Jianfeng He, Jiali Su, Zhiqiang Ou, Guixiu Liu, Rong Fu, Qiong Shou, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Jikai Zhang
Publikováno v:
Vaccine. 39:760-766
Background The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was approved for use in Chinese women aged 20–45 years in 2017. This Phase 3, open-label study (NCT03493542) aimed to assess immunogenicity and safety of the qHPV vaccin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96416883cc0459ad12a508364c3891cb
https://doi.org/10.1016/j.vaccine.2020.11.008
https://doi.org/10.1016/j.vaccine.2020.11.008
Autor:
Yuanzheng Qiu, You-Lin Qiao, Chao Zhao, Xing Xie, Yun Zhao, Wen Chen, Alfred J. Saah, Qiong Shou, Xueyan Liao, Shaoming Wang, Lihui Wei, Jihong Liu
Publikováno v:
Vaccine. 37:3617-3624
Background A quadrivalent human papillomavirus vaccine (qHPV; HPV6/11/16/18) has demonstrated efficacy and effectiveness worldwide. We report qHPV vaccine efficacy for up to 6.5 years after first administration among Chinese women 20–45 years of ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7dee9fd827ed357c6699a350aa1c13
https://doi.org/10.1016/j.vaccine.2018.08.009
https://doi.org/10.1016/j.vaccine.2018.08.009
Autor:
Qiong Shou, Minghuan Zheng, Susan S. Kaplan, Peng Luo, Xueyan Liao, Darcy A. Hille, Zhaojun Mo, Xiao Ma, Beth A. Arnold, Yi Mo
Publikováno v:
Vaccine. 37:1836-1843
Background A phase III, randomized, double-blind, placebo-controlled clinical study was conducted in China to assess the efficacy, safety, and immunogenicity of the pentavalent rotavirus vaccine (RotaTeqTM, RV5) among Chinese infants. The efficacy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2adfe22181bebb71174901fd5cc9963b
https://doi.org/10.1016/j.vaccine.2019.02.018
https://doi.org/10.1016/j.vaccine.2019.02.018
Autor:
Jihong Liu, Yun Zhao, Wen Chen, Jingran Li, Lihui Wei, Qiong Shou, Alfred J. Saah, Chao Zhao, Minghuan Zheng, You-Lin Qiao, Shaoming Wang, Xing Xie, Xueyan Liao
Publikováno v:
Vaccine. 37:889-897
Background A quadrivalent human papillomavirus (qHPV) vaccine (HPV6/11/16/18) has demonstrated efficacy and acceptable safety in international studies. However, these studies did not include participants from mainland China, which has a substantial b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a39ca2e3562b14cc750a7e10c3d031
https://doi.org/10.1016/j.vaccine.2018.12.030
https://doi.org/10.1016/j.vaccine.2018.12.030
Autor:
Xueyan Liao, Teng Huang, Youping Liu, Yanping Li, Qiong Shou, Minghuan Zheng, Rong-Cheng Li, Yuqin Liao
Publikováno v:
Vaccine. 36:1368-1374
Background This was an extension study of a randomized, double-blind, placebo-controlled immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV) (HPV 6, 11, 16, and 18) vaccine conducted in Chinese female subjects aged 9–45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ac5f0e06f0611ee16c9bb94ec47681a
https://doi.org/10.1016/j.vaccine.2018.02.006
https://doi.org/10.1016/j.vaccine.2018.02.006
Autor:
Yi Mo, Yuanzheng Qiu, Jianli Chu, Junhui Tao, Dingkai Wei, Xu Yang, Jilian Kong, Ming-Qiang Li, Susan S. Kaplan, Darcy A. Hille, Zhaojun Mo, Xueyan Liao, Micki Nelson, Botao Fu
Publikováno v:
Vaccine. 35:5897-5904
Background A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotaviru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eaec95d7cfd108f519687447f588b66
https://doi.org/10.1016/j.vaccine.2017.08.081
https://doi.org/10.1016/j.vaccine.2017.08.081
Publikováno v:
Human Vaccines & Immunotherapeutics
A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01bcb49479ee9e0285ec71182f18e45
https://doi.org/10.1080/21645515.2017.1285475
https://doi.org/10.1080/21645515.2017.1285475